OLD National Bancorp IN increased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 4.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,721 shares of the biopharmaceutical company’s stock after buying an additional 516 shares during the period. OLD National Bancorp IN’s holdings in Regeneron Pharmaceuticals were worth $3,669,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also modified their holdings of the company. Altfest L J & Co. Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $538,000. Landsberg Bennett & Dubbaneh LLC grew its holdings in shares of Regeneron Pharmaceuticals by 13.5% during the first quarter. Landsberg Bennett & Dubbaneh LLC now owns 815 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 97 shares during the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 16,826 shares of the biopharmaceutical company’s stock valued at $6,909,000 after buying an additional 216 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Regeneron Pharmaceuticals by 47.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 26,027 shares of the biopharmaceutical company’s stock valued at $10,687,000 after buying an additional 8,434 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 10.3% during the first quarter. Meeder Asset Management Inc. now owns 14,316 shares of the biopharmaceutical company’s stock valued at $5,877,000 after buying an additional 1,341 shares during the last quarter. 66.95% of the stock is owned by institutional investors.
A number of equities research analysts have recently weighed in on REGN shares. Robert W. Baird raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price objective on the stock in a report on Wednesday, August 7th. Credit Suisse Group dropped their price objective on shares of Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 8th. TheStreet lowered shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Wednesday, June 5th. Finally, Cowen reaffirmed a “hold” rating and issued a $353.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $398.25.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The firm had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the firm earned $5.45 EPS. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. As a group, sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 19.22 earnings per share for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the completion of the transaction, the director now owns 11,323 shares in the company, valued at approximately $3,464,045.39. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 11.84% of the stock is owned by corporate insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: What is the Russell 2000 Index?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.